AN ANALYSIS OF ULTRA-ORPHAN INITIAL ASSESSMENTS IN SCOTLAND COMPARED WITH OTHER KEY EUROPEAN HTA AGENCIES

被引：0
|
作者：
Foster, D. [1 ]
Walker, S. [1 ]
Phalguni, A. [1 ]
Jones, G. [1 ]
机构：
[1] PHMR Ltd, London, England
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSB264
引用
收藏
页码：S178 / S178
页数：1
相关论文
共 4 条
  • [1] ANALYSIS OF NICE AND US ICER HTA OUTCOMES FOR ULTRA-ORPHAN MEDICINAL PRODUCTS
    Dusza, M.
    Kloc, K.
    Remuzat, C.
    Francois, C.
    Toumi, M.
    [J]. VALUE IN HEALTH, 2019, 22 : S861 - S861
  • [2] ANALYSIS OF ORPHAN DRUGS REIMBURSEMENT IN MAJOR EUROPEAN HTA AGENCIES
    Houzelot, D.
    Heng, C.
    Perinaud, A.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A602 - A602
  • [3] GLOBAL HTA ASSESSMENTS OF ULTRA-ORPHAN PRODUCTS: A CASE STUDY OF ECULIZUMAB (SOLIRIS) AND IDURONATE-2-SULFATASE (ELAPRASE)
    Paul, A.
    Morawski, J.
    Spinner, D. S.
    Doyle, J. J.
    Faulkner, E. C.
    Ransom, J. F.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A431 - A431
  • [4] COMPARISON OF HEALTH TECHNOLOGY ASSESSMENTS AND TIME TO REIMBURSEMENT FOR ORPHAN DRUGS FROM FOUR HTA AGENCIES: OPPORTUNITIES AND CHALLENGES IN FRANCE, GERMANY, ENGLAND AND SCOTLAND
    Stefani, I
    Poon, C.
    Raj, N.
    Kelly, S.
    [J]. VALUE IN HEALTH, 2020, 23 : S757 - S757
1